InforMax, DNA Patenting, Wash U, NIGMS and NSF | GenomeWeb

In its 10-Q quarterly earnings report filed with the SEC on August 14, InforMax warned that it has been notified by Nasdaq that it is not in compliance with the $1.00 minimum bid listing requirement for continued listing on the Nasdaq National Market.

As a result, InforMax has until October 29, 2002, to demonstrate a closing bid price of at least $1.00 per share or more for a minimum of ten consecutive trading days. If the company fails to do so, it risks delisting.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.